3 citations,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
2 citations,
April 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The new method found new shared genetic areas linked to both Type 2 Diabetes and Prostate Cancer.
August 2019 in “The Journal of Urology” Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
71 citations,
April 2020 in “Journal of Cosmetic Dermatology” Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
45 citations,
January 2020 in “International Journal of Molecular Sciences” Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
218 citations,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
187 citations,
January 1994 in “The New England Journal of Medicine” Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.
110 citations,
April 2002 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.
88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
72 citations,
October 1998 in “Baillière's clinical endocrinology and metabolism” Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
51 citations,
June 1970 in “British journal of dermatology/British journal of dermatology, Supplement” Antiandrogens may help treat conditions like excessive hair growth, prostate tumors, male baldness, and acne by blocking male hormone effects.
42 citations,
May 2007 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism” Testosterone can build muscle and bone without enlarging the prostate when a specific enzyme is blocked.
41 citations,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
35 citations,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
30 citations,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
29 citations,
October 2020 in “eLife” Higher testosterone levels can increase the risk of certain diseases like type 2 diabetes in women and prostate cancer in men, but can also protect against autoimmune diseases and hair loss. It also affects body fat and bone density.
28 citations,
July 2017 in “Journal of Endocrinological Investigation” Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.
24 citations,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
24 citations,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
23 citations,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
21 citations,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
20 citations,
February 2009 in “Chemistry & Biodiversity” Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.
20 citations,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
20 citations,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
19 citations,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
16 citations,
October 2007 in “Andrologia” DHT is a strong androgen that may pose less risk to the prostate compared to testosterone.
16 citations,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.